Trastuzumab Deruxtecan,Capecitabine,Eribulin,Gemcitabine,Paclitaxel,Nab-paclitaxel
Daiichi Sankyo,AstraZeneca
['trastuzumab deruxtecan', 'rux,(-crux),(-trux)']
this is groundbreaking data showing trastuzumab deruxtecan is unaffected by subtype, esr1 or pik3ca mutations, or known cdk4/6i resistance marker status. this is a huge leap in our grasp of cancer treatments and genetic changes. #asco23. 
Our mission:To educate about Inflammatory Breast Cancer (IBC) & to promote & fund IBC research in the UK.